# **Special Issue**

# **Breast Cancer Theranostics**

# Message from the Guest Editors

Breast cancer is the most common invasive cancer in the world and the second leading cause of cancer deaths in females. The heterogeneity of breast cancer poses a challenge to its management. Various factors affect the prognosis, aggressive phenotype, and treatment response of breast cancer. A major challenge in the management of breast cancer is individual variability among patients. Recently, increased understanding of breast cancer biology had led to the identification of specific targets, expressed on cancer cells, that can be used for diagnosis and therapy at the molecular level of a specific individual, thus improving the therapeutic outcome. Therapostics is the combination of the diagnostic and therapeutic agents targeted at the same biomarker such as HER2. The advantage of the theranostic approach is that it identifies individuals who would benefit from a specific treatment and, thus, prevent the implementation of potentially futile treatments. This Special Issue of Diagnostics aims to provide an overview of the current developments in theranostics for breast cancer.

#### **Guest Editors**

Dr. Kwangsoon Kim

Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea

Dr. Chang Ik Yoon

Department of Surgery, College of Medicine, the Catholic University of Korea, Seoul 06591, Republic of Korea

# Deadline for manuscript submissions

closed (16 December 2022)



# **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



mdpi.com/si/125373

Diagnostics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
diagnostics@mdpi.com

mdpi.com/journal/diagnostics





# **Diagnostics**

an Open Access Journal by MDPI

Impact Factor 3.3 CiteScore 5.9 Indexed in PubMed



# **About the Journal**

## Message from the Editor-in-Chief

You are cordially invited to submit research articles, short communications, comprehensive reviews, case reports or interesting images for consideration and publication in *Diagnostics* (ISSN 2075-4418). *Diagnostics* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

### Prof. Dr. Andreas Kjaer

Department of Clinical Physiology, Nuclear Medicine & PET National University Hospital, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, Inspec, CAPlus / SciFinder, and other databases.

#### **Journal Rank:**

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Internal Medicine)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

